Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Painful diabetic neuropathy was associated with lower quality of life and higher rates of depression and anxiety than painless diabetic neuropathy.

Drugs like Ozempic and Wegovy could raise the risk of a rare form of vision loss, but we are still trying to unpick why ...

Semaglutide was tied to nonarteritic anterior ischemic optic neuropathy (NAION) risk vs. nonuse in adults with type 2 diabetes. New semaglutide users did not have higher NAION risk vs. most other ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...

Two large studies from the University of Southern Denmark (SDU) have found that Ozempic, a widely used medication for type 2 ...

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” ...

Read more. Semaglutide may raise risk for form of optic neuropathy in adults with type 2 diabetes Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic ...

Patients on semaglutide ( Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic ...

Increase in NAION associated with semaglutide use among individuals with type 2 diabetes. (HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly ...

Popular drugs for diabetes and weight loss could have an ... Seven of the patients had nonarteritic anterior ischemic optic neuropathy (NAION), which causes vision loss in one eye.